SEC Stock Data Quick Answer Alzamend Neuro, Inc. reported Net Income of -$4.51 million for fiscal year 2025. Alzamend Neuro, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Net Income -$4.51M+54.6% -$9.95M+33.1% -$14.88M-20.4% -$12.36M-145.0% -$5.05M-14.4% -$4.41M Diluted EPS -$11.32+91.4% -$132.33-478.1% -$22.89-16250.0% -$0.14 — — Total Assets $4.60M+628.8% $631.6K-89.3% $5.92M-59.2% $14.52M+398.4% $2.91M+60.6% $1.81M Cash … Read more
Quick Answer Alithya Group inc reported Gross Profit of $82.97 million for fiscal year 2020. Alithya Group inc Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2020 $82.97M +52.9% 2019 $54.28M +56.4% 2018 $34.69M — Alithya Group inc showed an increase of +52.9% in Gross Profit compared to the prior fiscal year. … Read more
Quick Answer Alithya Group inc reported Total Assets of $257.82 million for fiscal year 2020. Alithya Group inc Total Assets — Annual History Fiscal Year Total Assets YoY Change 2020 $257.82M +8.8% 2019 $236.87M — Alithya Group inc showed an increase of +8.8% in Total Assets compared to the prior fiscal year. Over the 2019–2020 … Read more
Quick Answer Alithya Group inc reported Total Assets of $257.82 million for fiscal year 2020. Alithya Group inc — Key Financials by Year Metric 2020 2019 2018 Total Assets $257.82M+8.8% $236.87M — Gross Profit $82.97M+52.9% $54.28M+56.4% $34.69M Alithya Group inc reported Total Assets of $257.82 million for fiscal year 2020. Alithya Group inc showed an … Read more
Quick Answer ALX ONCOLOGY HOLDINGS INC reported Shares Outstanding of 54.39 million shares for fiscal year 2025. ALX ONCOLOGY HOLDINGS INC Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 54.39M +2.5% 2024 53.05M +6.2% 2023 49.95M +22.2% 2022 40.86M +0.7% 2021 40.59M +1.9% 2020 39.84M +1158.1% 2019 3.17M — Quarterly Shares … Read more
Quick Answer ALX ONCOLOGY HOLDINGS INC reported Operating Income of -$104.02 million for fiscal year 2025. ALX ONCOLOGY HOLDINGS INC Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$104.02M +27.0% 2024 -$142.47M +16.3% 2023 -$170.28M -33.6% 2022 -$127.44M -52.5% 2021 -$83.56M -91.4% 2020 -$43.66M -127.6% 2019 -$19.18M -40.2% 2018 -$13.68M — … Read more
Quick Answer ALX ONCOLOGY HOLDINGS INC reported R&D Expense of $77.00 million for fiscal year 2025. ALX ONCOLOGY HOLDINGS INC R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $77.00M -33.8% 2024 $116.37M -17.9% 2023 $141.79M +44.1% 2022 $98.40M +63.5% 2021 $60.17M +107.8% 2020 $28.96M +77.6% 2019 $16.31M +44.7% 2018 $11.27M — … Read more
Quick Answer ALX ONCOLOGY HOLDINGS INC reported Stockholders Equity of $25.98 million for fiscal year 2025. ALX ONCOLOGY HOLDINGS INC Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $25.98M -77.1% 2024 $113.62M -40.1% 2023 $189.71M -28.0% 2022 $263.46M -27.4% 2021 $363.05M -15.5% 2020 $429.85M +708.5% 2019 -$70.64M -36.4% 2018 -$51.78M -34.8% … Read more
Quick Answer ALX ONCOLOGY HOLDINGS INC reported Long-Term Debt of $4.53 million for fiscal year 2025. ALX ONCOLOGY HOLDINGS INC Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2025 $4.53M -52.1% 2024 $9.47M -1.8% 2023 $9.64M +2.7% 2022 $9.39M +73.2% 2019 $5.42M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ … Read more
Quick Answer ALX ONCOLOGY HOLDINGS INC reported Cash and Equivalents of $16.37 million for fiscal year 2025. ALX ONCOLOGY HOLDINGS INC Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $16.37M -6.8% 2024 $17.57M -21.6% 2023 $22.41M -54.1% 2022 $48.82M -86.6% 2021 $363.67M -16.2% 2020 $434.22M +4715.6% 2019 $9.02M — … Read more